Combinations of paroxetine and 4- (S) - (4-Acetyl-piperazin-1-yl) -2- (R)- (4-fluoro-2-methyl-phenyl - piperidine-1-carboxylic acid (1- (R) - (3,5-bis-trifluoromethyl-phenyl) -ethyl) methylamide for treatment of depression and / or anxiety

Details for Australian Patent Application No. 2004229179 (hide)

Owner Glaxo Group Limited

Inventors Melotto, Sergio

Agent Davies Collison Cave

Pub. Number AU-A-2004229179

PCT Pub. Number WO2004/091616

Priority 0308968.7 17.04.03 GB

Filing date 16 April 2004

Wipo publication date 28 October 2004

International Classifications

A61K 031/445 - Non-condensed piperidines, e.g. piperocaine

A61P 025/00 Drugs for disorders of the nervous system

Event Publications

27 October 2005 PCT application entered the National Phase

  PCT publication WO2004/091616 Priority application(s): WO2004/091616

3 April 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004229181-Combinations comprising paroxetine and 2- (S) - (4-Fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid (1- (R)- (3,5-bis-trifluoro-2-methyl-phenyl) - ethyl)-methyl amide for treatment of depression and/or anxiety

2004229177-Orally disintegrating tablets